Loading...

OTLK OUTLOOK THERAPEUTICS INC US FDA Inspections 8-K Filing

TLK

TLK

OUTLOOK THERAPEUTICS INC

(OTLK)

2026 8-K

Public Offering Launch

Note Purchase Agreement

Stockholder Meeting Results

FDA Meeting Update

Delisting Notification

Financial Results Report

FDA Meeting Request

FDA Response Letter

Financial Results Disclosed

FDA Acknowledgement

FDA Resubmission Update

FDA Meeting Update

Management Change

FDA Response Letter

Financial Results Released

New Product Launches

Equity Offerings

Financial Statements

FDA Acknowledgment

FDA Resubmission

Financial Results

Debt Financing Deal

Warrant Inducement

Financial Results

Workforce Reduction

Clinical Trial Results

Financial Results

Marketing Authorization Gra...

Earnings Reports

Headquarters Relocation

Private Placement

Agreement with BTIG

Compliance Notice from Nasdaq

Private Placement

Stock Authorization Increase

Earnings Reports

Private Placement and Note ...

Financial Results Announcement

Organizational Realignment

Update on Type A Meetings w...

Financial Results Announcement

Agreement with BTIG, LLC

Earnings Reports

Amendment to Articles of In...

Financial Results Announcement

External Links:

On March 5, 2026, Outlook Therapeutics, Inc. announced it met with the FDA regarding a response letter on its drug ONS-5010 for treating wet AMD, which was previously addressed on December 30, 2025. This event is neutral and not significant for equity investors.

AI Assistant

OUTLOOK THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.